Adoptive T-cell therapy treats PML

Print Friendly, PDF & Email


JC virus protein (brown)
in a brain biopsy (glial
cells demonstrating PML)
Image by Marvin 101
Adoptive T-cell therapy has proven effective for treating progressive multifocal leukoencephalopathy (PML), according to research published in The New England Journal of Medicine. Researchers observed substantial improvements in three PML patients infused with donor T cells targeting the... [Read Article]
Print Friendly, PDF & Email

CDK8 inhibitor can fight AML, though it’s unclear how

Print Friendly, PDF & Email


Eliza Majewska, PhD
The CDK8 inhibitor SEL120 has demonstrated preclinical activity against acute myeloid leukemia (AML), but the agent’s mechanism of action is still unclear. Researchers found that several AML cell lines were “highly sensitive” to SEL120, and the inhibitor was active in primary patient samples. SEL120 also reduced tumor growth in mouse models... [Read Article]
Print Friendly, PDF & Email

NGS can predict AML relapse after HSCT

Print Friendly, PDF & Email


Bone marrow smear
from AML patient
Image from Armed Forces
Institute of Pathology
Next-generation sequencing (NGS) can be used to predict relapse in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplant (HSCT), according to research published in Blood. Researchers found that patients with a higher variant allele frequency (VAF) 21 days after... [Read Article]
Print Friendly, PDF & Email

Prophylaxis reduces bacteremia in some kids

Print Friendly, PDF & Email


Agar plate showing
staphyloccus infection
Photo by Bill Branson
In a phase 3 study, levofloxacin prophylaxis significantly reduced bacteremia in children with acute leukemias who received intensive chemotherapy. However, the risk of bacteremia was not significantly reduced with levofloxacin in another cohort of children who underwent hematopoietic stem cell transplant (HSCT). Sarah Alexander,... [Read Article]
Print Friendly, PDF & Email

Cell population appears to drive relapse in AML

Print Friendly, PDF & Email


From left to right: Study authors Lili Aslostovar, Allison Boyd, and Mick Bhatia
Photo by Kevin Patrick Robbins/McMaster University
Researchers believe they have identified cells that are responsible for relapse of acute myeloid leukemia (AML). These “leukemic-regenerating cells” (LRCs), which are distinct from leukemic stem cells (LSCs), seem to arise in response to chemotherapy. Experiments... [Read Article]
Print Friendly, PDF & Email

Team identifies potential immunotherapy target for AML

Print Friendly, PDF & Email


Ben Vincent, MD
Photo from the University
of North Carolina
New research could aid the development of immunotherapies tailored to patients with acute myeloid leukemia (AML) who are undergoing stem cell transplant (SCT). Researchers found they could use genetic sequencing and computer software to identify minor histocompatibility antigens (mHAs) known to occur in AML. The... [Read Article]
Print Friendly, PDF & Email

PLK1 inhibitor receives orphan designation for AML

Print Friendly, PDF & Email


AML cells
Image by Lance Liotta
The European Commission has granted orphan drug designation to onvansertib for the treatment of acute myeloid leukemia (AML). Onvansertib (formerly PCM-075) is an oral adenosine triphosphate competitive inhibitor of the serine/threonine Polo-like kinase 1 (PLK1) enzyme, which is overexpressed in hematologic and solid tumor malignancies. Trovagene, Inc., the company... [Read Article]
Print Friendly, PDF & Email